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ABSTRACT
With the advent of high-throughput and relatively inexpensive whole-genome 
sequencing technology, the focus of cancer research has begun to shift toward analyses 
of somatic mutations in non-coding cis-regulatory elements of the cancer genome. 
Cis-regulatory elements play an important role in gene regulation, with mutations in 
these elements potentially resulting in changes to the expression of linked genes. The 
recent discoveries of recurrent TERT promoter mutations in melanoma, and recurrent 
mutations that create a super-enhancer regulating TAL1 expression in T-cell acute 
lymphoblastic leukaemia (T-ALL), have sparked significant interest in the search for 
other somatic cis-regulatory mutations driving cancer development. In this review, we 
look more closely at the TERT promoter and TAL1 enhancer alterations and use these 
examples to ask whether other cis-regulatory mutations may play a role in cancer 
susceptibility. In doing so, we make observations from the data emerging from recent 
research in this field, and describe the experimental and analytical approaches which 
could be adopted in the hope of better uncovering the true functional significance of 
somatic cis-regulatory mutations in cancer.
INTRODUCTION
The field of cancer research has expanded 
remarkably since it was first suggested over a century 
ago, that cancer is caused by chromosomal abnormalities 
[1]. In the last few decades, numerous driver mutations 
have been identified, and comprehensive lists of cancer-
associated genes have been developed [2]. The primary 
research focus until recently has been almost entirely upon 
somatic mutations that lie within coding regions, which 
account for only ~2% of the genome. In the last few years 
however, there has been significant interest in somatic 
cancer mutations arising in the remaining 98% of the 
human genome which is non-coding. This expansion in 
focus has been driven primarily by advances in sequencing 
and other genomic technologies which have allowed 
scientists to mine previously unexplored regions of the 
genome. For example, the costs of sequencing a whole 
human genome have dropped rapidly in the past decade, 
with some sequencing endeavours having finally reached 
the famed US$1,000 mark [3]. These technological 
advances and reductions in sequencing costs mean that it 
is no longer a technical or financial barrier to sequence the 
entire genome of a large number of human cancers, and 
perform large-scale analyses with statistically significant 
outcomes.
In addition to reduced sequencing costs, 
technologies have advanced to allow for the increasingly 
accurate and detailed identification of regulatory regions 
in the non-coding genome. This is particularly important 
since the Encyclopedia of DNA Elements (ENCODE) 
project estimates that as much as 80% of the human 
genome may be functional [4], highlighting the potential 
relevance of somatic mutations within the non-coding 
genome. A comprehensive recent review of current 
computational methods available to identify cis-regulatory 
regions in the genome can be found at [5], and thus will 
not be addressed in this review.
Despite these significant advances, substantial 
challenges still remain in the interpretation of the findings 
of such non-coding genome-sequencing endeavours. For 
example, whole-genome sequencing (WGS) has revealed 
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that generally, intergenic DNA shows a rate of mutation 
which is almost twice as high as the rate in coding DNA, 
possibly due to a lack of selective pressure in non-coding 
regions [6], but also due to different rates and mechanisms 
of DNA repair across the genome [7–10]. This higher 
mutation rate makes it particularly difficult for researchers 
to identify driver non-coding mutations amongst the vast 
background of passenger mutations [2]. Furthermore, 
determining how a given mutation-harbouring region 
regulates expression, and which genes are affected, 
remains a major challenge.
In this review, we focus on the recent developments 
that have been made in the attempt to identify driver 
somatic mutations in cis-regulatory regions of the cancer 
genome. We first describe the initial discoveries of 
somatic cis-regulatory mutations occurring in sporadic 
cancers. We next make observations from the data that has 
emerged from recent discoveries, and critically review the 
methodology used to identify these non-coding mutations. 
Finally, we propose recommendations for future studies 
aimed at identifying and validating functionally relevant 
cis-regulatory mutations in the context of cancer.
FEATURES OF CIS-REGULATORY 
REGIONS
DNA in the eukaryotic genome is organised into 
chains of nucleosomes called chromatin [11]. Each 
nucleosome consists of approximately 147 bp of DNA 
wrapped around an octamer of histone proteins [12]. 
Nucleosomes package around two metres of DNA into the 
nucleus of each cell, with their precise positioning playing 
an important role in the regulation of DNA function, 
including DNA replication, repair and the expression of 
genes [13].
Gene promoters and enhancers are examples of cis-
regulatory regions (Table 1) that often show nucleosome 
depletion. At the promoters of highly expressed genes, 
nucleosomes are located just upstream and downstream 
of the transcription start site (TSS), thereby creating a 
nucleosome depleted region. This feature is thought to 
facilitate access for transcription factors (TFs) to bind 
[14]. TFs are trans-acting DNA binding proteins that 
bind regulatory elements, either enhancing or repressing 
transcription [15]. The function of a gene promoter can be 
influenced by other regulatory regions such as enhancers 
which, when active, also show nucleosome depletion and 
can recruit TFs. Enhancers can physically interact with 
gene promoters by looping the intervening chromatin 
to juxtapose the two regions (Figure 1). This allows 
enhancers to regulate the activity of promoters that may 
be several hundred kilobases away. One hypothesis is that 
variants or somatic mutations occurring in cis-regulatory 
regions can impact upon gene expression by altering the 
unique binding sites that are recognised by TFs.
Nucleosome depleted regions can be detected 
as DNase I hypersensitive (DHS) sites due to their 
sensitivity to cleavage by the DNase I enzyme. DHS 
regions can be identified genome-wide by DNase 
I sequencing (DNase-seq). Enhancers and promoters can 
be differentiated through the signature of specific histone 
marks flanking the DHS, which can be identified by 
chromatin immunoprecipitation sequencing (ChIP-seq). 
For example, H3K4me3 and H3K4me1 typically mark 
promoter and enhancer regions respectively [16, 17]. In 
addition, H3K27ac and H3K9me3 identify activated and 
repressed cis-regulatory regions respectively [16–18]. 
Therefore, the combinatorial use of DNase-seq and 
ChIP-seq allows researchers to identify the nucleosome 
occupancy and specific histone marks which define the 
presence and activity of certain cis-regulatory regions. In 
addition, ChIP-exo can be adopted. This technique was 
recently used to locate somatic cancer mutations in TF 
binding sites [19] as it can identify, at almost base pair 
resolution, the binding locations of DNA-binding proteins 
[20]. Techniques such as these can help to accurately 
identify a cis-regulatory region within which a mutation 
lies, and so allow for a better determination of the analyses 
which may be needed to assess the functional role of such 
mutations within the cancer genome.
INITIAL DISCOVERIES: SOMATIC 
MUTATIONS IN CIS-REGULATORY 
REGIONS IN CANCER
The primary focus of this review is on the role of 
somatic point mutations and small insertions or deletions 
(indels) within regulatory regions in cancer. We do not 
focus on the role of large-scale structural rearrangements 
(due to the differences in the techniques needed to 
identify and analyse these forms of variation), nor do we 
address germline variation in detail. Though, it is worth 
highlighting that most single nucleotide polymorphisms 
(SNPs) identified by genome-wide association studies 
(GWAS) to be significantly associated with cancer and 
disease are located within non-coding regions of the 
genome [21]. In contrast to specific somatically acquired 
mutations however, germline variants may be part of a 
larger haplotype in linkage disequilibrium. Therefore, it 
is not always possible to pinpoint the pathogenic germline 
variant amongst several within a haplotype. Even so, 
multiple examples exist of SNPs in putative cis-regulatory 
regions which are linked with increased risk of cancer 
development, for examples see [22–34]. This suggests 
that we should also expect to find somatic cis-regulatory 
mutations that play a role in cancer development. Despite 
this, the prevalence of somatic cis-regulatory mutations as 
cancer drivers has not yet been established. In this section, 
we discuss the initial discoveries of such mutations as they 
are relevant to further research conducted in the field.
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TERT promoter mutations acting as cancer 
drivers
The first and arguably most significant discovery of 
somatic cis-regulatory mutations in cancer were recurrent 
somatic mutations found in the promoter of the telomerase 
reverse transcriptase (TERT) gene. In 2013, two articles 
[23, 35] were published simultaneously that documented 
independent discoveries of cancer-associated variation 
within the TERT promoter. Two recurrent somatic 
mutations (chr5:1,295,228 C > T and chr5:1,295,250 
C > T) were identified in 71% of WGS malignant 
melanomas analysed [35]. The TERT promoter mutations 
were initially identified as worthy of further research 
because they were highly recurrent, mutually exclusive 
with each other, and occurred in the absence of a high 
background of passenger mutations in the surrounding 
region [35]. The mutations alter the expression of TERT 
by creating de novo motifs for the binding of GA-binding 
protein (GABP) which is part of the E twenty-six (ETS) 
family of TFs [35, 36] (Figure 2). A germline mutation 
(chr5:1,295,161 T > G) was also found in the TERT 
promoter which segregated disease in individuals in a 
melanoma-prone family [23].
It is well established that cancer cells have high 
telomerase activity levels, but few coding mutations have 
been identified within the TERT gene [37]. However, over-
expression of TERT enables telomere renewal, which is 
necessary for cellular immortalisation, a hallmark of 
cancer [38]. This seminal finding represented the first 
identification of recurrent somatic mutations within 
a promoter region in cancer [35] and has led to further 
studies aimed at determining the prevalence of TERT 
promoter mutations in other cancers [39–44]. In the 
past two years, the same two somatic TERT promoter 
mutations, together with additional TERT promoter 
mutations, have been identified in numerous other cancers, 
with particularly high prevalence in glioblastoma (62%) 
and bladder cancer (59%) [45]. The clinical significance 
of these findings is highlighted by the current investigation 
of TERT promoter mutations as potential biomarkers for 
cancer prognosis [37].
Enhancer-altering mutations in the development 
of leukaemia
In 2014, small heterozygous somatic insertions 
containing TF motifs for the MYB transcription factor 
were identified in tissue samples and cell lines of T-cell 
acute lymphoblastic leukaemia (T-ALL) [46]. The 
mutations cause the spontaneous formation of a super-
enhancer capable of binding MYB, recruiting other 
important TFs and causing mono-allelic overexpression 
of T-cell acute lymphocytic leukemic protein 1 (TAL1) 
[46]. These mutations thus drive tumorigenesis in T-ALL, 
having been discovered in an attempt to account for the 
mono-allelic overexpression which had been observed in 
some T-ALL samples despite a lack of any translocations 
at the TAL1 locus or TAL1 abnormalities [46, 47]. This 
research is highly significant as it is the first description 





The core promoter is the DNA region to which transcriptional machinery binds [15]. It includes 
some of the following: TATA box, initiator element (Inr), and downstream promoter element [15]. 
The Inr is the most common feature, being present in approximately half of all promoters [91]. 
Proximal promoter elements typically lie immediately upstream and within close proximity of the 
core promoter element [15].
Enhancer
Enhancers are specific DNA sequences that can regulate the activity of a promoter. The first 
enhancer was discovered in the SV40 tumour virus genome [92], and the first human enhancer 
was identified in the immunoglobulin heavy-chain locus [93]. Secondary enhancers have also been 
identified, and may act as ‘shadow enhancers’, ensuring that enhancer activity continues even if 
environmental conditions change and affect primary enhancer function [94–96].
Super-enhancer
Super-enhancers are defined as a grouping of enhancers that are situated within close proximity of 
each other and combinatorially bind transcription factors [76]. They tend to be differentiated from 
regular enhancers through a particular occupancy by cofactors [76]. However, there is still debate 
about whether super-enhancers really are a truly separate class of regulatory region, or whether they 
are simply strong enhancers that operate generally in the same way as a typical enhancer [97].
Insulator Insulators are DNA sequences that act to partition the genome into regions defined by transcriptional activity [15].
Silencer Silencers are specific DNA sequences that halt transcription by serving as binding sites for negative transcription factors (also called ‘repressors’) [15].
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Figure 1: Enhancer-promoter looping occurs over vast distances of DNA. A. Inactive enhancer and promoter. The enhancer 
for a given gene can potentially lie up to thousands of kilobases away from the promoter which it regulates. When in the inactive state, the 
promoter and enhancer may not be in close proximity. B. Enhancer-promoter looping. In the active state, the enhancer and promoter form a 
loop of DNA, enabling the enhancer to contact the promoter and recruit transcription factors (TFs) to the region, leading to gene expression. 
The DNA loop can form even when the enhancer and promoter are located at vast distances from each other.
Figure 2: TERT promoter mutation alters transcription factor binding and gene expression. A. Wild-type TERT promoter.
The TERT gene body is marked by a black box, with the intronic region identified by a dotted line. The wild-type DNA sequence for a 
small portion of the promoter region is indicated. B. Mutant TERT promoter. The mutated TERT promoter sequence is given, featuring 
a C > T mutation which creates a consensus binding motif for an ETS transcription factor. The sequence created is identical for both the 
chr5:1,295,228 and chr5:1,295,250 C > T mutations identified by Huang, et al. [35]. The first 7 bases of the ELK1 (ETS family) binding 
motif is shown for illustrative purposes (obtained from the Jaspar database [88]). This image indicates the way in which the mutations can 
create a binding site for an ETS transcription factor, leading to transcription factor binding and increased TERT gene expression.
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of somatic driver mutations which affect enhancers 
in cancer [48] and thus uncovered a mechanism in 
carcinogenesis which is potentially common but yet to be 
characterized [46].
While structural variation is not the focus of this 
review, it is still worth noting the recent identification 
of recurrent 3q rearrangements in some acute myeloid 
leukaemia (AML) samples [49]. These rearrangements 
result in the repositioning of an enhancer element which 
causes cancer development by simultaneously activating 
EVI1 and causing haplo-insufficiency of GATA2 in AML 
[49]. As chromosomal rearrangements are a factor in 
virtually all cancer types [50], this finding suggests that 
the structural rearrangement of enhancer elements may be 
a potentially common mechanism of cancer development.
OBSERVATIONS FROM RECENT 
DISCOVERIES
The identification of the recurrent TERT and TAL1 
mutations raises the possibility that other cis-regulatory 
regions may acquire somatic mutations that contribute 
to cancer by similar mechanisms. By understanding the 
methodology adopted in the discovery of these mutations, 
researchers are better able to investigate whether other cis-
regulatory mutations are functionally relevant in cancer 
development. However, despite scientifically rigorous 
analyses of WGS data from a range of cancers [6, 51, 52], 
non-coding somatic mutations have yet to be identified 
with such robust links to cancer development as the TERT 
and TAL1 regulatory examples. In the following sections, 
we describe the research efforts undertaken to identify 
further examples of cis-regulatory somatic mutations in 
cancer. We conclude by drawing together these findings 
to make recommendations for future research directions.
High numbers of somatic point mutations in cis-
regulatory regions of cancer genomes
It has been established that the somatic cancer 
mutation rate in DHS regions is generally lower than in 
other genomic regions due to increased accessibility of 
regulatory DNA by repair mechanisms [9]. Nevertheless, 
recent research has indicated that there are a large number 
of somatic cancer mutations in regulatory DNA. For 
example, Melton et al. [52] found that after correcting 
for mapping errors, across cancer types, almost 40% of 
somatic mutations were within portions of the genome 
annotated to be regulatory. Further, Mathelier et al. [53] 
found enrichment for somatic point mutations within 
TF binding sites when compared with coding exons in 
a majority of B-cell lymphoma samples. While most 
regulatory mutations are likely to be passengers, the shear 
prevalence of somatic mutations in regulatory regions of 
cancer genomes, together with the large portion of the 
genome that may have regulatory function, highlights 
the important pool of candidate mutations from which 
cancer drivers may yet be identified. Interestingly, it is 
worth noting that the same pattern of elevated rates of 
somatic point mutations in regulatory regions has not 
been observed with respect to indels [53], suggesting that 
a different mechanism that may be at play regarding indel 
accumulation, repair or selection.
Despite the high number of somatic point mutations 
in regulatory regions, the impact of such mutations on 
gene expression is yet to be determined genome-wide. 
However, recent attempts have been made to establish 
the portion of regulatory mutations which are functional 
in a single genome [54]. Poulos et al. [54] used reporter 
assays to screen promoter mutations in an unbiased 
manner within the melanoma cell line COLO-829, finding 
that almost 20% of mutations altered promoter activity 
in mutant compared to wild-type sequences. The high 
number of somatic cancer mutations in regulatory regions, 
together with the relatively high percentage of functional 
promoter mutations identified in a single genome, 
highlights the urgent need to consider the role that these 
mutations may have on cancer development.
Promoter mutations in other cancer-
associated genes
Many potentially important cis-regulatory mutations 
have been identified proximally to cancer-associated 
genes. These mutations were prioritised since they lie 
in mutational hotspots [6], are recurrent [51] or are 
linked with an expression change in an associated gene 
[55]. Further establishing this association, in a cohort of 
B-cell lymphoma samples, Mathelier et al. [53] found 
that genes harbouring mutations in TF binding sites 
within their promoters were significantly enriched for 
genes in apoptosis and other oncogenic pathways. The 
high prevalence of mutations in the regulatory regions 
of genes involved in cancer-associated pathways has 
been highlighted in the published literature on numerous 
occasions [6, 52, 53, 55, 56]. Some of these analyses 
simply noted that cancer-related genes were included 
within their findings, while others performed some form of 
statistical measure. However, it would be of great interest 
to determine whether somatic mutations in regulatory 
regions of cancer-related genes are truly enriched in cancer 
genomes across multiple cancer types, and whether this is 
particularly the case in either promoters or enhancers.
One explanation for the identification of many 
promoter mutations in cancer-associated genes is 
that these genes may be more sensitive to the effects 
of point mutations in their promoters. Perhaps such 
mutations result in small but important changes in 
expression of these potential onco- or tumour-suppressor- 
genes. As a result, the mutations may be selected for 
within proliferating cancer cells and so drive cancer 
development. However, the distinct mutagenic potential 
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of the cis-regulatory regions of cancer-associated genes is 
yet to be determined.
Recurrent mutations are often not associated 
with gene expression change
While a number of genes have been found to 
harbour recurrent mutations, many, including cancer-
associated genes, do not have clear links with expression 
change [6, 51, 52]. Even in cases where increased 
somatic mutation accumulation in a regulatory region 
has been correlated with a change in expression of 
the associated gene, causation has been difficult to 
establish [56]. As an example of this issue, Fredriksson 
et al. [51] used WGS data from 14 different cancers to 
identify mutations within 500 bp of a TSS that were 
recurrent in at least 5 tumours, but which existed in 
a ± 5 kb region of low overall mutation density. Two 
genes found to have nearby mutations are PLEKHS1 and 
DPH3. PLEKHS1 harbours two mutations close to its 
TSS (chr10:115,511,590 and chr10:115,511,593, both 
predominantly C > T [6]), while the region surrounding 
the DPH3-proximal mutations (most recurrent at 
chr3:16,306,505 C > T) had the lowest background 
mutation rate of all the recurrent mutations identified 
[51]. Despite strong selection criteria being applied, and 
the recurrence of the mutations identified, PLEKHS1 was 
not over- or under- expressed in mutant samples when 
compared to wild-type [51]. Regarding DPH3, the gene 
appeared to be more highly expressed in DPH3 promoter 
mutants than wild-type samples in a small cohort 
(n = 38) of melanomas, but no difference in expression 
was observed when a larger cohort (n = 173) was 
interrogated [51]. This finding is unexpected, particularly 
considering the similarities that exist between the TERT 
promoter mutations and the DPH3-proximal mutations: 
DPH3 is a candidate cancer-associated gene (a potential 
tumour-suppressor); the mutations are recurrent in 
melanomas (13%); and the mutations alter a predicted 
ETS TF binding site [51]. With such features, it would 
otherwise be expected that the DPH3-proximal mutations 
would be prime candidates to be a potential driver in 
cancer development. However, the lack of association 
with expression changes suggests that a more complex 
interaction may be at play.
Fredriksson et al. [51] suggested a number 
of alternate hypotheses to account for the lack of 
correlation between the recurrent DPH3-proximal 
mutations and expression. These hypotheses should 
also be considered when assessing other cis-regulatory 
mutations. For example, temporal patterns in expression 
may alter during cell-cycle progression or under specific 
conditions, such as at times of cellular stress. As such, 
a mutation may only become relevant under certain 
conditions. Alternatively, a mutation may co-operate 
with other mutations in the genome, in a similar way 
to SNP interactions in germline DNA. In fact, both 
the DPH3-proximal mutations and the TERT promoter 
mutations significantly co-occur with NF1 and BRAF 
mutations, respectively [51]. Compound or cell-cycle-
specific gene expression effects from somatic cancer 
driver mutations in cis-regulatory regions are yet to be 
established. However, if these hypotheses are correct, 
the effects of any mutation on gene expression could 
be subtle and not readily measured in heterogeneous 
tissues. Importantly, this would limit the effectiveness 
of non-specific genome-wide gene expression analysis – 
a common tool used today from databases such as The 
Cancer Genome Atlas (TCGA) or the International 
Cancer Genome Consortium (ICGC) [57]. These 
suggestions are supported by the results of a survey 
of somatic promoter mutations in the genome of the 
melanoma cell line COLO-829 [54]. This study found 
a mutation in the promoter of NDUFB9 which was 
responsible for decreased promoter activity in reporter 
assays [54]. The mutation was recurrent in other 
melanoma genomes and significantly co-occurred with 
coding NF1 mutations, but a corresponding association 
with altered gene expression was not apparent in mutant 
samples from a TCGA cohort [54].
In addition to biological explanations, samples 
size and statistical power remain limiting factors when 
performing large-scale analyses of regulatory mutations 
in cancer [6, 51, 52]. When mutations are present 
at low frequency or in only a single cancer type, the 
mutant sample sizes available for expression analyses 
make robust conclusions difficult to reach. This is 
further compounded by the need to perform extensive 
corrections for multiple testing when determining 
genome-wide expression correlations, requiring that 
the strength of associations between mutation and 
expression change be highly significant. This issue may 
be partially overcome as sample sizes increase and new 
statistical methods are developed to analyse such data.
An alternative interpretation of the data however, 
is that recurrence alone may not be a good discriminator 
between functional and silent mutations in the non-
coding genome. Instead, mutation recurrence within 
the non-coding genome may more often implicate bases 
that are particularly prone to mutagenesis than it does 
cancer driver mutations. This could particularly be the 
case in cis-regulatory regions, as TF binding may induce 
mutagenesis and prevent DNA repair [58, 59], and could 
account for mutations which are recurrent in the absence 
of functional consequence. The interaction between TF 
binding, DNA repair and somatic mutation accumulation 
is yet to be fully elucidated, but this consideration 
highlights the need to functionally validate the role 
in cancer development of any recurrent mutations 
identified.
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RECOMMENDED STRATEGIES FOR 
IDENTIFYING FUNCTIONAL CIS-
REGULATORY MUTATIONS
The need to develop a research pipeline with 
appropriate experimental validation
Research into the functional impact of somatic 
cis-regulatory mutations in cancer is still in its infancy, 
with only a handful of studies performed to date, for 
examples see [6, 51–54, 56, 60]. However, it has already 
become apparent that when different criteria are applied 
to prioritise candidate mutations for further analysis from 
a somewhat common pool, different sets of mutations can 
be highlighted [6, 52]. This can be partly attributed to 
differences in the samples used for analyses, with many 
WGS sample sizes from a single cancer type still being 
less than ideal. However, in many cases, different window 
sizes have been used in order to determine regulatory 
regions that are recurrently mutated. For example, 
some criteria that have been used to determine regional 
recurrence include mutations within 50 bp of each other 
[6] or mutations within windows of 10 bp [52], 100 bp 
[51] or up to 1 kb [53]. Additionally, Smith et al. [56] 
developed a computational method known as SASE-
hunter to study signatures of accelerated somatic evolution 
(SASE). This method was particularly applied to study 
SASE within a 6 kb region (-5 kb to +1 kb of the TSS) 
to identify promoter regions with more mutations than 
expected by chance alone [56]. Consideration of regional 
recurrence in addition to base-pair recurrence is highly 
important, but this variation in the size of the regions 
focused upon in analysis demonstrates the need for the 
development and validation of a research pipeline which 
can accurately identify biologically relevant clusters of 
cancer driver mutations from among the vast background 
of passenger mutations in the non-coding cancer genome.
Such a research pipeline will undoubtedly involve 
experimental validation in a relevant in vivo biological 
context to distinguish between functional and silent 
cis-regulatory somatic mutations. This experimental 
validation could take on a variety of forms. For example, 
both of the landmark studies of TERT promoter mutations 
in melanoma [23, 35] used luciferase reporter assays 
to show increased activity of mutant over wild-type 
sequences. Additionally, the TAL1 [46] and GATA2/
EVI1 [49] enhancer studies both utilised CRISPR/Cas 
genome editing technology [61] to show that the enhancer 
alterations were causative of the gene expression changes 
they identified. Notably also, allele-specific expression 
analyses utilising RNA-seq (Figure 3) or pyrosequencing 
[62] can be further used to demonstrate the pathogenic 
role of a somatic cis-regulatory mutation in vivo. This type 
of analysis can take on a variety of forms, with RNA-seq 
data having been used recently in a study of colorectal 
cancers [63]. This study investigated the allelic ratios 
between samples in heterozygous locations, in order to 
identify genes with somatic alterations in their regulatory 
regions [63].
More recent work in the field has utilised genome-
wide RNA-seq data from TCGA database rather than 
site-specific experimental validation to determine gene 
expression changes. Experimental analysis in the form 
of reporter assays has been used in a limited number 
of circumstances [52, 54, 55], but many studies have 
taken purely bioinformatic approaches. While these 
computational analyses were scientifically rigorous 
and TCGA transcriptomic data is a useful resource, as 
discussed previously, it is yet to be established whether 
analyses of heterogeneous whole-tumour data alone 
are sufficient to uncover truly functional cis-regulatory 
somatic mutations with potentially subtle impacts on 
gene expression, in the absence of targeted experimental 
work. This fact is particularly notable with regard to the 
recurrent mutations proximal to PLEKHS1 that were 
discussed previously. These mutations were separately 
identified in two independent studies [6, 51] but, despite 
both using TCGA bladder cancer gene expression data, 
Fredriksson et al. [51] concluded no change in expression 
between wild-type and mutant groups, while Weinhold 
et al. [6] found a significant decrease in expression in 
mutant samples when compared to wild-type. It remains 
to be seen whether any expression change (or lack thereof) 
will persist in experimental scenarios for the PLEKHS1-
proximal mutations. A validated research pipeline, 
once developed, will indicate the most appropriate 
type of experimental analysis that ought to accompany 
bioinformatic predictions of functional cis-regulatory 
mutations.
Transcription factor motif alteration and gene 
expression changes
The TERT promoter mutations create motifs for 
ETS TF binding, and so it was hypothesised that increased 
binding of ETS factors in the mutated promoter led to 
increased TERT expression and cellular immortalization 
[35] (Figure 2). Subsequent studies have adopted slightly 
different methodologies and criteria in their research, 
but two studies used gene expression data to specifically 
investigate somatic mutations that alter ETS factor 
motifs [6, 51]. This method of analysis interestingly led 
to the identification of a potential link between the TERT 
promoter and control of CLPTM1L gene expression [51]. 
A systematic analysis of the mutations that alter other 
important TF motifs, in addition to ETS, may identify 
further promising candidate cancer driver mutations 
and associations worthy of investigation [6]. In fact, 
subsequent analyses of mutations in other TF motifs has 
led to the finding that CTCF/cohesion [19] and CEBP 
[52] binding sites are significantly mutated – both with 
potential links to tumorigenesis. Interestingly, such 
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analyses of other TF motifs, has also noted that some 
specific bases in a given motif are more often mutated, 
suggesting a potential underlying selective pressure on 
such mutations [52].
In all analyses of mutations in TF motifs however, 
TF motif redundancy ought to be considered. TF motif 
redundancy is a phenomenon which describes the 
many regulatory regions that contain a multitude of 
compensatory TF binding motifs [64]. Some regulatory 
mutations that remove TF motifs may not alter gene 
expression because compensatory binding elsewhere in 
the promoter region negates the effects of the altered TF 
motif, as illustrated in Figure 4. In addition, regulatory 
region redundancy may also be at play, whereby a gene is 
regulated by a number of different cis-regulatory regions. 
Melton, et al. [52] suggest that while this may increase 
the opportunity for regulatory somatic mutations that 
impact on the expression of a given gene to be acquired, it 
could also have the result of protecting against the effects 
of mutation. Therefore, while a mutation may still be 
pathogenic, TF and regulatory region redundancy ought to 
be considered, especially when designating functionality 
to a mutation in the absence of experimental validation.
Identification of the genes associated with 
enhancer elements
Expression changes linked with TF alterations 
caused by somatic mutations can only be analysed in detail 
if the putative cis-regulatory region in which the mutation 
lies is able to be linked to an associated gene. This is a 
relatively simple process for promoter regions which 
are generally located upstream and in close proximity 
to the genes they regulate [15]. However, difficulties 
arise when enhancers are the target of analyses, as these 
regions engage with genes over vast distances [65] 
(Figure 1). Enhancer elements have been traditionally 
linked to genes by proximity, typically using the Genomic 
Figure 3: Analysis of allele-specific gene expression from DNA- and RNA-sequencing data. A. DNA and whole-genome 
sequencing data. An example of a promoter mutation (red vertical bar) identified by whole-genome sequencing. This mutation is heterozygous 
and is in cis (i.e. on the same allele: allele B) with an informative SNP (vertical orange bar) within exon 1 of the gene. This is determined 
by the presence of both variants on single DNA molecules (indicated by arrows) from the whole-genome sequencing reads (grey bars, 
lower panel). B. RNA and RNA-sequencing data. Figure shows detection of the same informative SNP in transcribed molecules using 
RNA-sequencing. The relative expression of the two alleles is determined by comparing the number of sequenced molecules containing 
this variable SNP (grey bars, lower panel). This in turn infers the potential impact of the promoter mutation on gene expression. In this case, 
the promoter mutation appears to be associated with activation of the expression of this allele.
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Regions Enrichment of Annotations Tool (GREAT) [66]. 
More recently however, studies have been increasingly 
adopting FANTOM5 – a data atlas containing mappings 
of enhancer-gene associations across the genome 
based on cap analysis of gene expression (CAGE) data 
correlations with putative target gene TSSs [67]. While 
the application of FANTOM5 data has allowed for more 
accurate designations of enhancer-gene associations, the 
atlas is not exhaustive for all enhancers genome-wide, 
nor for all cell-types available for study. It is due to these 
reasons perhaps, that there have not yet been large scale 
studies of somatic mutations from WGS data that occur 
specifically within enhancer regions of cancer genomes. 
In fact, to our knowledge, only a handful of somatic point 
mutations in enhancer regions have been experimentally 
linked to changes in gene expression, and potentially 
cancer development [52, 55, 60].
In cases where there is no FANTOM5 data available 
for a putative enhancer region, various experimental 
techniques are available to associate it with a genic region 
of the genome. These techniques involve chromosome 
conformation capture-based technologies such as 
Chromatin Interaction Analysis by Paired-End Tag (ChIA-
PET) sequencing [68], Chromosome Capture Conformation 
(3C) [69], Circular Chromosome Conformation Capture 
(4C) [70], Carbon-Copy Chromosome Conformation 
Capture (5C) [71] and Hi-C [72]. These methods allow 
for the study of the spatial organization of genomic DNA 
by fixing chromatin interactions and sequencing ligation 
products to identify associations between distant parts of 
the genome [73]. In fact, 4C was used to identify the effects 
of the oncogenic EVI1/GATA2 enhancer rearrangement in 
AML [49].
Researchers may also need to use experimental 
techniques, such as chromatin conformation capture, 
ChIP-seq or DNase-seq, when they aim to determine 
sample-specific or somatically-created enhancer-gene 
associations. A potential approach that can be used to 
identify functional somatic mutations that create novel 
cis-regulatory regions is to make use of this sample-
specific data to identify potential regulatory regions unique 
to specific cancer samples, and then seek to identify 
somatic variants within these regions. For example, 
Mansour et al. [46] used sample-specific data to identify 
the somatic TAL1 enhancer alteration, as it did not fall into 
an enhancer region previously described in CD34 cells. 
As shown in Figure 5A, only by using sample-specific 
DNase-seq data from a cell line possessing the mutation 
Figure 4: Transcription factor redundancy can impact on the functional effect of some mutations. A. Wild-type promoter, 
with transcription factor redundancy.The wild-type promoter region depicted in this image has two GGAA motifs which can be recognised 
by the illustrated transcription factor. Only one motif is being utilised by the wild-type promoter, and the gene is being expressed. B. Mutant 
promoter, with transcription factor redundancy allowing for compensatory binding. A G > A somatic mutation means that the mutant 
promoter region has lost one GGAA motif. However, in this simplified scenario, the illustrated transcription factor will bind instead to the 
GGAA motif that was previously redundant in the wild-type promoter, meaning that gene expression does not change in the associated  gene.
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(for example, Jurkat) could the DHS region created by 
the enhancer be identified. In fact, sequencing reads from 
DNase-seq can, in the absence of WGS, be used to identify 
somatic mutations uniquely present in DHS regions. 
Using the TAL1 enhancer in Jurkat cells as an example, 
this concept is illustrated in Figure 5B, whereby clipped 
DNase-seq reads corresponding to the insertion mutation 
can be found within the enhancer.
Increasing data availability in analyses
Recent analyses have been performed on combined 
WGS data from many different cancer types (for 
example, 26 cancers [6], 14 cancers [51], 12 cancers 
[56] and 8 cancers [52]). However, no single cancer 
yet has enough individual samples with WGS to allow 
for the identification of non-coding mutations at low 
frequency in only a single cancer type [6]. In fact, many 
recent analyses have cited a need for more sequencing 
or matched expression data in order to draw firmer 
conclusions or identify mutations present at lower 
frequencies [6, 51, 52, 56]. It is worth noting that 
many sample sizes can be increased by the inclusion 
of whole-exome sequencing (WXS) data, which can 
often extend past the intended capture region [74] or 
span the intergenic space between adjacent genes and 
unintentionally overlap promoters (Figure 6). WXS data 
is therefore, a potential source of information that can be 
used to boost the statistical power of analyses of somatic 
promoter mutations while awaiting the WGS of further 
cancer samples. WXS data has already been used to some 
extent to establish the recurrence of certain promoter 
mutations [6, 51, 54], but to the best of our knowledge, 
there has been no large-scale application in non-coding 
genome research.
However, increases in data availability will 
inevitably also lead to increasing complexity. As the pool 
of potential candidate driver mutations identified from 
cancer WGS datasets increases, better bioinformatic 
screening will be required to determine those mutations 
which ought to be segregated for targeted experimental 
analysis. This highlights the importance of accounting for 
mutational heterogeneity (using such models as MutSigCV 
[75]) and false positive mutation calls arising due to 
mapping errors [52]. Without such analyses, candidate 
recurrent somatic mutations may be spuriously identified 
if they simply fall into mutagenic hotspots or regions for 
which the mapping of reads is difficult.
Further, if recurrence continues to be adopted as a 
key indicator of potential driver mutations, cases must be 
considered where a given gene is regulated by a number 
of cis-regulatory regions located in different areas of the 
genome. Each region may potentially harbour only a small 
number of somatic mutations that wouldn’t be identified 
by simple statistical analyses. However, the mutations may 
be arranged in such a way that the associated gene will 
be influenced by a statistically significant number of cis-
regulatory mutations across samples. Alternatively, it may 
also be possible for a large genomic window to harbour a 
complex pattern of mutations within a single sample, but 
not be detected due to the decreased statistical power of 
analyses of such large regions [51]. Therefore, analyses 
performed on large datasets may potentially miss genes 
with such mutational patterns, or a significant number of 
mutations in their cis-regulatory regions, if the biological 
function and interaction of these regions is not considered.
Strategies to improve targeting of cis-regulatory 
regions and mutations
Additional criteria may help researchers to 
determine the best candidates for experimental analyses. 
For example, with many oncogenes and tumour suppressor 
genes regulated by strong enhancers, it is worth noting 
that strong enhancers are more sensitive to alterations that 
decrease the activity of their transcriptional regulators 
[48]. With this in mind, perhaps research focus could be 
particularly drawn to super-enhancers and other strong 
enhancers in the cancer genome to allow for more effective 
targeting of potential candidate mutations [48]. Strong 
enhancers such as super-enhancers can be identified by the 
presence of particularly high levels of binding by Mediator 
(Med1) [76].
For further improved targeting, analysis of 
mutations falling into ultra-sensitive regions [77] may 
elucidate the most deleterious mutations. Additionally, 
on the assumption that highly conserved bases will be the 
most sensitive to mutations, human population-variation 
data could be used to better target specific bases, rather 
than cross-species conservation [77], as many regions that 
are conserved in a variety of mammals are not active in 
humans [78].
Finally, it is worth considering the interaction 
between somatic mutations in regulatory regions of genes 
whose protein-coding exons are often mutated in cancer. 
As previously discussed, co-occurrence of coding and 
regulatory mutations [51, 54] may lead to previously 
unknown cancer mechanisms. It is possible that exonic 
and promoter mutations may form complementary 
mechanisms by which expression is altered in cancer. 
Mathelier et al. [53] has suggested this with reference to 
ID3, a gene with TF binding site mutations and recurrent 
coding mutations in Burkitt lymphoma. Hence, promoter 
or enhancer mutations in the regulatory regions of genes 
that are often mutated in a given cancer type may provide 
a good filtering mechanism for candidate driver somatic 
mutations.
AVAILABLE WEB SERVERS
For researchers less familiar with, or with less 
access to, genome-wide cancer datasets, a number of 
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Figure 5: Gain of TAL1 enhancer mutation, along with DNase-seq data and sequencing reads. A. DNase-seq data around 
TAL1-STIL locus. DNase-seq data (obtained from the ENCODE database [89]) is shown for a number of cell-types, indicating that the 
gain of an enhancer is unique to Jurkat cells. All tracks are fixed at 200 read coverage. The Jurkat aligned reads that correspond show a 
number of mismatches at the insertion site. B. Visualisation of soft-clipping reads. Soft-clipping DNase-seq reads from the Jurkat cell line 
(visualisation taken from the Integrative Genomics Viewer). Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer 
(IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013; 14: 178–192. Robinson JT, Thorvaldsdottir 
H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011; 29: 24–26. show a clear 
presence of reads corresponding with the insert. This demonstrates the way in which cis-regulatory variants can be identified from DNase-
seq data alone.
Figure 6: Read coverage for a sample gene using whole-exome sequencing (WXS) data, showing that sequencing can 
extend into intronic and promoter regions. This figure depicts the read coverage of a WXS TCGA skin cutaneous melanoma sample 
(example used: TCGA-DA-A960) obtained from TCGA database. The region selected surrounds the RPS27 gene, in which a recurrent 
5′ UTR mutation was recently discovered in melanoma through the use of WXS data [90]. The approximate promoter (indicated by a DHS 
region) is shown using DNase-seq peak data from the COLO-829 malignant melanoma cell line, obtained from the ENCODE database 
[89]. Visualisation of all tracks is taken from the Integrative Genomics Viewer. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative 
Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013; 14: 178–192. Robinson 
JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011;  
29: 24–26.
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web servers exist [55, 79–83] that provide annotations 
of putative cis-regulatory variations (see Table 2). These 
tools can allow researchers to identify the mutations in a 
dataset that are the most likely to be functional. A number 
of these tools provide scorings of each mutation or 
variant analysed, allowing researchers to better prioritise 
candidate mutations. Of note, the FunSeq2 server 
additionally incorporates network analysis to connect 
non-coding variants into protein-protein, regulatory and 
phosphorylation networks, providing a measurement that 
indicates the likelihood of a variant being deleterious 
[79]. Additionally, while the OncoCis web server [55] 
does not score mutations, it is specifically designed for the 
annotation of somatic cancer mutations in cis-regulatory 
regions. It utilises cell-type-specific histone marks to 
identify mutations in putative promoters and enhancers. 
The need to account for tissue specificity when identifying 
and characterizing cis-regulatory regions is becoming 
increasingly evident [53, 55, 77, 84] as mutations may 
be deleterious only in certain tissues [77] and many cis-
regulatory regions are not ubiquitously involved in gene 
expression across tissue types [67]. This tool thus helps to 
identify the somatic mutations in a dataset that are most 
likely to be functional in a relevant cell-type.
CONCLUDING REMARKS
No cis-regulatory somatic mutations have yet 
been identified in recent studies that have such strong 
associations with altered gene expression and cancer 
development as the regulatory mutations impacting TERT 
and TAL1. Perhaps this is because somatic cis-regulatory 
Table 2: Tools available for analysis of the functional role of non-coding variants and somatic 
mutations
Tools Description* Web link
CADD [83]
Combined Annotation-Dependent 
Depletion (CADD) integrates a 
number of annotations to provide 
a C score which represents the 
likelihood of deleteriousness of a 
single nucleotide variant or small 
indel. CADD can be used for both 
somatic and germline variants, in 




FATHMM-MKL is a machine 
learning approach that uses a variety 
of predictive measures such as 
conservation, histone modification, 
transcription factor binding and 
GC content. It can be applied in 
the analysis of both somatic and 
germline variants in coding and non-




FunSeq2 is an analysis pipeline 
which provides a weighted scoring 
system based on conservation, 
transcription factor binding gain- or 
loss-of-function events, recurrence, 
enhancer-gene associations and 
network centrality. FunSeq2 has 





mutations play only a minor role in cancer development, 
with the TERT promoter mutations being exceptional 
in their recurrence both within and across cancer types. 
However, with increasing evidence that germline variants 
play a driver role in cancer risk, this conclusion seems 
unlikely. It is our opinion that it is more probable that 
other cis-regulatory mutations exist at lower prevalence, 
or in only one cancer type, and simply have not yet 
been identified. Thousands of WGS samples will likely 
be required to accurately identify driver mutations that 
are present at low frequencies among the background 
of passenger mutations in the cancer genome [85]. For 
this reason, further analysis will be required in order to 
uncover the true role of cis-regulatory somatic mutations 
in cancer development.
This research is vital, as cancer driver mutations 
in cis-regulatory regions may potentially serve as 
biomarkers or drug targets [37, 86]. For example, drugs 
targeting enhancer regions can be used in therapy in cases 
where cancer is driven by aberrant enhancer regulation 
[49]. In fact, tumour-specific super-enhancers are 
preferentially targeted by drugs that act on components 
of the transcriptional complex [46], and this area 
will potentially produce breakthrough results. Other 
targets include the TFs that are recruited to the mutated 
cis-regulatory regions of important cancer driver genes, 
which may provide a means of halting cancer progression 
[87]. Thus, research into cis-regulatory somatic cancer 
mutations may produce potentially fruitful therapeutic 
targets. It is our hope that the recommendations made in 
this review for future research direction will help in this 
endeavour.
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Tools Description* Web link
GWAVA [81]
Genome-Wide Annotation of 
Variants (GWAVA) is a tool 
which prioritises analysis of non-
coding variants, and is designed 
to be applied for both germline 
and somatic variants. It uses 
a variety of both genomic and 
epigenomic annotation methods to 
provide a GWAVA score allowing 





OncoCis is a webserver which 
allows researchers to identify cis-
regulatory somatic mutations by 
using conservation, transcription 
factor binding and cell-type-specific 
genome and epigenome datasets. 
The tool is designed for use with 
non-coding somatic mutations from 




RegulomeDB scores regulatory 
variants to prioritise those variants 
that have functional consequences. 
The tool applies such data as eQTL, 
ChIP-seq, DNase-seq and TF motifs. 
It is targeted at the annotation of 
germline variants but can be used in 
analysis of somatic mutations. It is 
designed for use in annotating non-
coding variants.
http://regulomedb.org/
*See reference or web link provided for a fuller description of each of the tools listed.
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